These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population. Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025 [TBL] [Abstract][Full Text] [Related]
5. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368 [TBL] [Abstract][Full Text] [Related]
6. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955 [TBL] [Abstract][Full Text] [Related]
7. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance. Zhang B; Zhang M; Shen C; Liu G; Zhang F; Hou J; Yao W Cell Death Dis; 2021 Sep; 12(10):856. PubMed ID: 34545063 [TBL] [Abstract][Full Text] [Related]
8. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201 [TBL] [Abstract][Full Text] [Related]
9. Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers. Bhattacharya S; Harris HL; Islam R; Bodas S; Polavaram N; Mishra J; Das D; Seshacharyulu P; Kalluchi A; Pal A; Kohli M; Lele SM; Muders M; Batra SK; Ghosh PM; Datta K; Rowley MJ; Dutta S Cell Death Dis; 2024 Aug; 15(8):617. PubMed ID: 39183332 [TBL] [Abstract][Full Text] [Related]
10. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708 [TBL] [Abstract][Full Text] [Related]
11. ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Qian C; Yang Q; Rotinen M; Huang R; Kim H; Gallent B; Yan Y; Cadaneanu RM; Zhang B; Kaochar S; Freedland SJ; Posadas EM; Ellis L; Di Vizio D; Morrissey C; Nelson PS; Brady L; Murali R; Campbell MJ; Yang W; Knudsen BS; Mostaghel EA; Ye H; Garraway IP; You S; Freeman MR Nucleic Acids Res; 2024 Jul; 52(13):7740-7760. PubMed ID: 38932701 [TBL] [Abstract][Full Text] [Related]
12. Targeting RET Kinase in Neuroendocrine Prostate Cancer. VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304 [TBL] [Abstract][Full Text] [Related]
13. Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression. Zhang M; Sun Y; Huang CP; Luo J; Zhang L; Meng J; Liang C; Chang C Cell Death Dis; 2021 Sep; 12(10):855. PubMed ID: 34545067 [TBL] [Abstract][Full Text] [Related]
14. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity. Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568 [TBL] [Abstract][Full Text] [Related]
15. Molecular model for neuroendocrine prostate cancer progression. Chen R; Dong X; Gleave M BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310 [TBL] [Abstract][Full Text] [Related]
17. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network. Lee AR; Gan Y; Tang Y; Dong X EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395 [TBL] [Abstract][Full Text] [Related]
18. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400 [TBL] [Abstract][Full Text] [Related]
19. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals. Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806 [TBL] [Abstract][Full Text] [Related]
20. Loss of Long Noncoding RNA Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]